Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.3K
Overview
51.3K
Cancer Vaccines01:30

Cancer Vaccines

978
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
978
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

860
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
860
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

548
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
548
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

953
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
953

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model.

Cell reports. Medicine·2026
Same author

Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis.

Scientific reports·2026
Same author

Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells.

Frontiers in immunology·2026
Same author

The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection.

iScience·2026
Same author

Evaluation of 1<sup>st</sup> WHO anti-malaria reference reagent for competition ELISA harmonisation and development of ADAMSEL analytical platform.

Biologicals : journal of the International Association of Biological Standardization·2025
Same author

MetE: a promising protective antigen for tuberculosis vaccine development.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.0K

Insights and challenges in tuberculosis vaccine development.

Helen McShane1

  • 1The Jenner Institute, University of Oxford, Oxford, UK.

The Lancet. Respiratory Medicine
|August 17, 2019
PubMed
Summary
This summary is machine-generated.

Developing a tuberculosis vaccine is critical to combatting global health threats. Recent progress offers hope, but challenges in licensure and deployment remain, requiring continued collaboration and funding.

More Related Videos

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

558
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K

Related Experiment Videos

Last Updated: Jan 20, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.0K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

558
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Global Public Health

Background:

  • Tuberculosis (TB) remains a leading cause of death globally, necessitating urgent development of effective vaccines.
  • The World Health Organization's End TB Strategy highlights the crucial role of vaccination in achieving eradication targets.
  • Despite significant research advancements over two decades, TB vaccine development faces persistent hurdles.

Purpose of the Study:

  • To review the current state of tuberculosis vaccine research and development.
  • To identify progress and remaining challenges in creating a universally effective TB vaccine.
  • To emphasize the need for new evaluation tools, collaboration, and sustained funding.

Main Methods:

  • Review of recent tuberculosis vaccine research and clinical trial outcomes.
  • Analysis of challenges in vaccine licensure and global deployment.
  • Discussion of potential facilitators for vaccine development and implementation.

Main Results:

  • Substantial progress in TB vaccine research over the past 20 years.
  • Clinical trial results from 2018 indicate growing optimism for vaccine efficacy.
  • Significant obstacles persist in the path to a licensed and widely available TB vaccine.

Conclusions:

  • While recent advancements are encouraging, the path to an effective tuberculosis vaccine requires overcoming substantial challenges.
  • New tools for vaccine evaluation are crucial for accelerating progress.
  • Sustained international collaboration and funding are essential for the successful development and deployment of a TB vaccine.